Lawrence Eichenfield - 08 Jun 2023 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
08 Jun 2023
Net transactions value
$0
Form type
4
Filing time
12 Jun 2023, 09:03:59 UTC
Previous filing
13 Jun 2022
Next filing
20 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Stock Option (right to buy) Award $0 +10,384 $0.000000 10,384 08 Jun 2023 Common Stock 10,384 $5.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.